Loading news...
Moderna settled a yearslong patent dispute with Arbutus Biopharma and a subsidiary of Roivant Sciences. The news sent Moderna shares jumping.
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals with potential additional payment contingent on the outcome; no accrual recorded for potential additional payment as loss is not considered probable 2026 year-end cash and cash equivalents now expected to be in the range of $4.5 - $5.0 billion CAMBRIDGE, MA / ACCESS Newswire / March 3, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has entered into a settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH resolving all litigation worldwide, including between the parties in the U.S. District Court for the District of Delaware. The settlement resolves all worldwide Arbutus/Genevant litigation related to Spikevax® and mRESVIA® and provides certainty going forward for Moderna's full infectious disease portfolio, including mNEXSPIKE®, mCOMBRIAX® and its future vaccine pipeline, with no future royalties owed.
Moderna ( MRNA ) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50.
Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.
If you purchase a 10-year U.S. Treasury bond, you'll get an annual yield of around 4%.
Banco Santander S.A. raised its stake in Moderna, Inc. (NASDAQ: MRNA) by 22.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 215,894 shares of the company's stock after buying an additional 39,056 shares during the period. Banco Santander S.A. owned approximately 0.06%
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive CHMP opinion mCOMBRIAX will be made available in the European Union, subject to final European Commission authorization and national regulatory and access procedures CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union for mCOMBRIAX® (mRNA-1083), Moderna's combination vaccine indicated for active immunization for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. "The CHMP's positive opinion represents an important milestone for respiratory virus vaccination and for Moderna, with the introduction of the world's first flu plus COVID combination vaccine.
Europe's medicines regulator on Friday recommended granting marketing authorisation to mCombriax, making Moderna's messenger RNA vaccine the world's first combined shot for people aged 50 and older against COVID and seasonal influenza in a single dose.
Moderna has faced good and bad times in recent years. Most recently, the FDA refused to review Moderna's flu candidate -- then reversed course.
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increased by approximately $4.0 billion over the past 6 days and now sits at $20 billion.
Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line.
Weekly Market HighlightsWeekly performance was volatile at the extremes, with 876 stocks gaining more than 10% while 776 stocks declined by more than 10%.Marke
Philippe Laffont bought shares of CoreWeave in the first quarter of last year and recently closed that position. The investor favors tech stocks and innovators.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its holdings in shares of Moderna, Inc. (NASDAQ: MRNA) by 70.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,703 shares of the company's stock after selling 66,213 shares during the